What 608 SFDA Inspection Findings Reveal About QMS Readiness

The number 608 is striking, but it is not the whole story. In its 2024 statistical report on medical-device manufacturer inspections, the Saudi Food and Drug Authority reported 72 inspections of local and overseas manufacturers and 608 nonconformities. Major findings represented 44% of the total. This is not a market-wide failure rate, and it does not predict the outcome of any individual inspection. It is a historical view of what inspectors found across a defined set of visits in one year.

The figures come directly from the SFDA 2024 manufacturer-inspection statistical report. Any reuse of the numbers should preserve that attribution and limitation.

The pattern matters more than the headline

The report records 3 critical, 267 major and 338 minor nonconformities. A minor finding is not irrelevant; a cluster of minor findings can expose a systemic weakness in document control, training or follow-through. A major finding, meanwhile, is rarely closed by rewriting an SOP. A defensible response shows that the organization understood the cause, contained the immediate issue, implemented proportionate action and checked whether the action worked.

The report should therefore not be reduced to a league table of weak clauses. Its practical value is showing where a written system can separate from daily work: unclear authority, records that do not prove execution, metrics that never reach management, or post-market information that does not feed back into risk management.

To turn this analysis into a product-specific plan, review Technical File and Regulatory Readiness Review and the related regulatory insight.

Management responsibility is an operating system

Within the report's management-responsibility findings, responsibility, authority and communication accounted for the largest share. That matters because quality cannot sit inside one department. During an inspection, the real questions are who owns the decision, how an issue reaches leadership, what management did after reviewing it and whether resources were actually assigned.

That reading is consistent with SFDA guidance MDS-G024, which connects ISO 13485 with Saudi regulatory expectations and places accountability for QMS effectiveness with top management.

A six-path readiness test

Trace a real record instead of polishing folders

A useful internal inspection does not start by rereading every SOP. It selects a real case and follows the evidence end to end. Take a recent complaint: was it logged, assessed for reportability, linked to the device and lot, evaluated against risk, and escalated to CAPA where justified? Then trace a supplier or product change through verification, technical documentation, regulatory assessment and labeling. A broken link is a readiness gap even when every procedure exists.

Under MDS-REQ10, SFDA visits can include licensing, routine, follow-up, reactive, device-verification and surprise inspections. Follow-up visits verify corrections and corrective or preventive action. Readiness is therefore an operating condition, not a pre-audit event.

How Basier supports readiness

Basier starts with the establishment's licensed activity, product scope and regulatory role. We then build an evidence map connecting SFDA requirements, internal procedures and actual records. We test traceability paths, examine open findings and distinguish an immediate correction from a corrective action that needs cause analysis and effectiveness review. The output is not a promise of a successful inspection; it is a defensible view of priorities and an accountable closure plan.

When an inspection is close, depth should follow risk. Address first the gaps that affect product safety, regulatory compliance, traceability and the response to complaints or incidents. Then document what was completed, what remains, who owns it and when it will close.

References: [1] [2] [3]